Journal of Hepatocellular Carcinoma最新文献

{"title":"Social Support, Quality of Life, and Financial Toxicity Among Patients with Hepatocellular Carcinoma.","authors":"Shuyue Liu, Yawen Xie, Tiantian Li, Yanxia Huang, Danting Xu, Linli Cai, Yizhen Fu, Jinbin Chen, Yaojun Zhang, Jia Huang, Zili Hu","doi":"10.2147/JHC.S523284","DOIUrl":"10.2147/JHC.S523284","url":null,"abstract":"<p><strong>Background & aims: </strong>Despite the significant hepatocellular carcinoma (HCC) patient population, gaps exist in understanding their survivorship journey.</p><p><strong>Methods: </strong>Patients diagnosed with HCC at all stages were recruited at Sun Yat-sen University Cancer Center from August 1, 2023, to December 30, 2023. The comprehensive score for financial toxicity (COST) was used to assess financial toxicity, the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) was used to assess quality of life (QOL), and the Social Support Rating Scale (SSRS) was used to assess social support. Separate multiple linear regression models were performed to assess the association among social support, FT, and QOL.</p><p><strong>Results: </strong>Of the 250 approached HCC patients, 239 completed the survey and were included in this study. Most respondents were male (192 [80.3%]), of Han nationality (235 [98.3%]), and married (214 [89.5%]). Higher social support (β, 0.13; 95% CI, 0.01 ~ 0.26; P = 0.048) was independently associated with lower FT (higher COST score). Lower FT (β, 0.74; 95% CI, 0.49 ~ 0.99; P < 0.001) and social support (β, 1.47; 95% CI, 0.73 ~ 2.21; P < 0.001) were independently associated with higher QOL. Social support not only directly affected the QOL (b = 0.62, <i>P</i><0.001, 95% CI [0.33-0.90]) but also indirectly affected the QOL through FT (b = 0.14, 95% CI [0.03-0.28]).</p><p><strong>Conclusion: </strong>The findings of this survey study suggest that social support was associated with higher QOL and lower FT in HCC patients. Future investigations focusing on targeted social support interventions may enhance QOL and reduce FT in HCC patients.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1711-1723"},"PeriodicalIF":3.4,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335290/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>GALNT14</i> Genetic Variants Harbor Differential Prognostic Values Linking to Distinct Macrophage Cell Types in Hepatocellular Carcinoma.","authors":"Yu-De Chu, Pei-Huan Ho, Wei-Ting Chen, Yu-Lin Shih, Ming-Wei Lai, Chao-Wei Hsu, Chau-Ting Yeh","doi":"10.2147/JHC.S530180","DOIUrl":"10.2147/JHC.S530180","url":null,"abstract":"<p><strong>Purpose: </strong>Surgical resection is the primary curative treatment for hepatocellular carcinoma (HCC), while high recurrence rates can limit the prognosis, emphasizing the need for reliable biomarkers. <i>GALNT14</i>-rs9679162 is associated with postoperative prognosis and therapeutic responses. However, relying on one single nucleotide polymorphism (SNP) greatly limits its predictive power. This study aims to identify an SNP panel to improve prognosis prediction and explore its role in modulating tumor-infiltrating immune cells (TIICs).</p><p><strong>Patients and methods: </strong>We included 345 HCC patients underwent surgical resection: 15 in the exploration cohort and 330 in the validation cohort. Genome-wide association study (GWAS) and PCR-based genotyping identified SNPs in linkage disequilibrium (LD) with rs9679162. The link between <i>GALNT14</i> expression and TIICs was analyzed. Prognostic evaluation was performed using Kaplan-Meier survival analysis and Cox proportional hazards models, with statistical significance set at P < 0.05.</p><p><strong>Results: </strong>GWAS identified 39 SNP loci linked to rs9679162 and associated with postoperative prognosis. In the validation cohort, 10 SNPs were selected and categorized into four groups. Eight SNPs showed strong LD with rs9679162 and were significantly associated with recurrence-free survival and metastasis-free survival. The predictive performance of the combined SNP groups surpassed that of rs9679162 alone, with the most effective stratification achieved by combining groups-2+3. Additionally, <i>GALNT14</i> expression, linked to the identified genotypes, correlated with M2-macrophage abundance within TIICs.</p><p><strong>Conclusion: </strong>An SNP panel in LD with rs9679162, particularly from group-2 (rs62140629, rs4952033, rs56284247) and group-3 (rs9679162, rs6752303), serves as a prognostic marker for HCC. GALNT14 expression was associated with M2-macrophages, suggesting an immune-regulatory mechanism.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1695-1710"},"PeriodicalIF":3.4,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beta-Catenin Mutations Can Impact on the Interplay Between Tumor and Immune Cells and Hepatic Microbiota in Hepatocellular Cancer.","authors":"Yu Ota, Julia Driscoll, Anneliese R Hill, Irene K Yan, Tushar Patel","doi":"10.2147/JHC.S524341","DOIUrl":"10.2147/JHC.S524341","url":null,"abstract":"<p><strong>Introduction: </strong>Emerging evidence links alterations in the tumor microbiome to therapeutic responses to immunotherapy. Alterations in β-catenin are among the most frequently observed oncogenic drivers of hepatocarcinogenesis and are associated with T-cell exclusion. However, their effect on the immune cell environment and microbiome in hepatocellular cancer is not well understood. We hypothesized that β-catenin could modulate the immune microenvironment through alterations in the secretome and release of extracellular vesicles (EV) that mediate tumor and immune cell interactions and increase tumor growth within regions with attenuated immune activity and reduced microbial diversity.</p><p><strong>Methods: </strong>We used a synthetic transgenic murine model of β-catenin-driven hepatocarcinogenesis to analyze microbiome composition, diversity, and immune cell profiles in vivo. Tumor and stool samples were collected from mice with early- or late-stage hepatocellular carcinoma and were used for profiling.</p><p><strong>Results: </strong>The microbiome associated with intrahepatic tumors differs from that in non-tumoral regions, normal liver tissues, and gut tissues. Constitutive β-catenin expression modulates lipopolysaccharide-mediated signaling in macrophages and alters the secretion of immunomodulatory chemokines and cytokines. Tumoral immune cell profiles differed from those in hepatic tissues. EV-mediated signaling between immune cells and epithelial cells with mutant β-catenin and immune cells modulates immune cell populations in vitro and in vivo.</p><p><strong>Conclusion: </strong>Mutations in β-catenin can drive immune responses through EV-based tumor cell-immune cell interactions to modulate both the tumor microflora and immune microenvironment. A potential strategy to augment responses to immunotherapy for hepatocellular cancer could target these interactions to restore microbial diversity or immune cell infiltration within the tumor microenvironment.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1677-1693"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12325116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A CT-Based Deep Learning Radiomics Scoring System for Predicting the Prognosis to Repeat TACE in Patients with Hepatocellular Carcinoma: A Multicenter Cohort Study.","authors":"Yanmei Dai, Sheng Zhao, Qiong Wu, Jin Zhang, Xu Zeng, Huijie Jiang","doi":"10.2147/JHC.S525920","DOIUrl":"10.2147/JHC.S525920","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to construct a novel retreatment scoring system to screen patients with hepatocellular carcinoma (HCC) who could benefit further after transarterial chemoembolization (TACE).</p><p><strong>Patients and methods: </strong>310 patients with HCC were retrospectively recruited from three hospitals. The training and validation cohort were randomly selected from Center 1, and two external testing cohorts comprised from Center 2 and Center 3, respectively. Deep learning score and handcrafted radiomics signatures were constructed from the pretreatment arterial-phase and venous-phase CT images. The optimal features were screened using SelectKBest and LASSO regression. The AUC of the optimal combined model, consisting of HBsAg, five radiomics features, and DLscore, was 0.97, 0.89, 0.76, and 0.84 in the four cohorts, respectively. The optimal model was well calibrated. The prediction performance was assessed with respect to receiver operating characteristics, calibration, and decision curve analysis. Kaplan-Meier survival curves based on the scoring system were used to estimate the overall survival (OS).</p><p><strong>Results: </strong>The optimal combined model consisted of HBsAg, 5 radiomics signatures, and DLscore, which AUC in four cohorts was 0.97, 0.89, 0.76, and 0.84, respectively, with good calibration. Decision curve analysis confirmed that the combined model was clinically useful. After Cox regression analysis of these characteristics, the scoring system (HBsAg-Radscore-DLscore, HRD) was significantly associated with OS in patients with HCC, and was superior to the traditional ART score and ABCR score between high and low-risk patients.</p><p><strong>Conclusion: </strong>Deep learning and radiomics had good performance in predicting the OS of patients with HCC treated with repeated TACE. The HRD score is a potentially valuable and intelligent prognostic scoring system better than the traditional score.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1647-1659"},"PeriodicalIF":3.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-Cell RNA Sequencing Integrated with Bulk-RNA Sequencing Analysis Reveals Prognostic Signatures Based on PANoptosis in Hepatocellular Carcinoma.","authors":"Jiyin Wang, Xue Yin, Ziyi Li, Pu Liang, Yipeng Wang, Xingling Li, Wenying Qiao, Chaoyang Xiong, Minghang Yu, Xiaoyan Ding, Xi Wang","doi":"10.2147/JHC.S533777","DOIUrl":"10.2147/JHC.S533777","url":null,"abstract":"<p><strong>Purpose: </strong>Drug resistance severely compromises therapeutic efficacy in hepatocellular carcinoma (HCC); however, the selection of precise treatment strategies for patients remains a critical unmet clinical need. This study investigated PANoptosis-related mechanisms underlying HCC progression to identify actionable therapeutic targets and optimize patient-specific treatment outcomes.</p><p><strong>Patients and methods: </strong>Multi-omics analysis (single-cell/bulk RNA sequencing) combined with machine learning was used to identify the PANoptosis-related prognostic features. The association of PANoptosis-related expression with the tumor immune microenvironment and drugs was explored using bioinformatic analysis and experimental studies.</p><p><strong>Results: </strong>High PANoptosis risk exhibited immunosuppressive microenvironments and therapeutic resistance. The PANoptosis-related gene YIF1B has emerged as a dual prognostic biomarker and tumor driver that promotes proliferation, and is linked to immune dysfunction and drug resistance.</p><p><strong>Conclusion: </strong>YIF1B may be a promising therapeutic target. This PANoptosis framework bridges molecular mechanisms to clinical management, offering strategies for personalized HCC therapy and overcoming treatment resistance.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1661-1676"},"PeriodicalIF":3.4,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318859/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144784458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct Roles of HHLA2 and PD-L1 in the Immune Cell and Prognosis of Hepatocellular Carcinoma.","authors":"Chun-Hua Wang, Shi-Lu Chen, Xia Yang, Ting Wu, Li-Li Liu, Jing-Ping Yun","doi":"10.2147/JHC.S513033","DOIUrl":"10.2147/JHC.S513033","url":null,"abstract":"<p><strong>Background: </strong>HHLA2, a member of the B7 family, is extensively expressed in various cancers and plays a pivotal role in modulating the immune microenvironment. However, its prognostic significance in hepatocellular carcinoma (HCC) remains poorly understood. This study aims to elucidate the expression patterns of HHLA2 and PD-L1 in HCC, their associations with tumor-infiltrating lymphocytes (TILs), and their impact on clinical outcomes.</p><p><strong>Methods: </strong>Immunohistochemistry (IHC) was employed to evaluate HHLA2 and PD-L1 expression in 547 HCC tissue samples. PD-L1 positivity was defined as ≥1% membranous or cytoplasmic staining. Hematoxylin and eosin (H&E) staining was utilized to quantify TILs (percentage/area), while IHC was used to measure the densities of CD3+, CD4+, and CD8+ TILs (cells/mm²).</p><p><strong>Results: </strong>HHLA2 and PD-L1 exhibited similar positivity rates. HHLA2 positivity was associated with older age, lower alpha-fetoprotein (AFP) levels, well-differentiated tumors, and improved overall survival (OS). HHLA2 expression was inversely correlated with stromal TIL density. In contrast, tumor cell (TC)-PD-L1 and inflammatory cell (IC)-PD-L1 positivity were positively correlated with higher stromal TIL density and increased levels of CD3+, CD4+, and CD8+ TILs. Patients with HHLA2(+)/PD-L1(-) status demonstrated the longest OS. A novel classification system based on HHLA2/PD-L1 expression identified distinct immune profiles and prognostic subgroups.</p><p><strong>Conclusion: </strong>HHLA2 significantly influences the immune microenvironment of HCC and serves as an independent prognostic marker. The combined assessment of HHLA2 and PD-L1 expression facilitates risk stratification, providing a framework to optimize immunotherapy strategies. These findings contribute to the advancement of precision medicine in the management of HCC.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1633-1645"},"PeriodicalIF":3.4,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12306544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144742261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia.","authors":"Mohamed Asiri, Abdullah BinAbdu, Abdulrahman Al-Ammar, Abdulaziz Abdullah Alsuaib, Abdullah Al-Shehri, Abdullah Abdulaziz Almazyad, Ammar M Aloufi, Najd AlGazlan, Haneen Saleh Alrajih, Mohammad Alkaiyat, Husam I Ardah, Husam Shehata, Kanan Alshammari","doi":"10.2147/JHC.S525984","DOIUrl":"10.2147/JHC.S525984","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate survival outcomes and prognostic factors of systemic therapies in advanced hepatocellular carcinoma (HCC) within Saudi Arabia, addressing the limited regional data.</p><p><strong>Patients and methods: </strong>A retrospective review of 670 HCC patients was utilized. 130 patients with advanced HCC who received first-line systemic therapy were identified, and data on demographics, tumor characteristics, treatment regimens, laboratory findings, and survival outcomes were collected. Treatment response and survival outcomes were evaluated using RECIST criteria and the Kaplan-Meier method, respectively.</p><p><strong>Results: </strong>Our population's mean age was 70.4, majority being males. Sorafenib was the most frequently used, then nivolumab and the atezolizumab-bevacizumab (Atezo+Bev) combination. Median overall survival (OS) varied by treatment: patients receiving Atezo+Bev showed the longest OS, followed by nivolumab and sorafenib. No statistically significant difference was observed in survival. Despite the small sample size, this trend suggests a potential OS benefit with Atezo+Bev, particularly in patients with advanced hepatic dysfunction. Furthermore, 39.1% of patients had elevated alpha-fetoprotein (AFP) levels and 26.8% had sarcopenia. Multivariate analysis highlighted the elevated neutrophil-to-lymphocyte ratio (NLR) as a significant predictor of worse survival, reinforcing its relevance as a prognostic marker in HCC. Although sarcopenia demonstrated an improved survival trend, it was not statistically significant. Adverse events were consistent, with elevated AST, anorexia, and fatigue frequently observed.</p><p><strong>Conclusion: </strong>This study illustrated Atezo+Bev's potential in improving OS in advanced HCC, with an elevated NLR identified as a key marker for poor prognosis. These findings support the need for prospective studies to confirm and expand regional insights into the management of HCC.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1623-1632"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Natural Bioactive Compounds Targeting the Wnt/β-Catenin Pathway for the Treatment of Hepatocellular Carcinoma.","authors":"Haoyu Tian, Peng Wang, Haibo Shao","doi":"10.2147/JHC.S523261","DOIUrl":"10.2147/JHC.S523261","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with limited treatment options and poor prognosis. The Wnt/β-catenin signaling pathway is a key regulator of cellular proliferation, differentiation, and stem cell maintenance, and is frequently dysregulated in HCC, contributing to tumor progression, metastasis, and drug resistance. Natural bioactive compounds (NBCs) have emerged as promising treatments due to their multi-targeted mechanisms, low toxicity, and ability to modulate key oncogenic pathways. This review examines the potential of NBCs to target the Wnt/β-catenin pathway in HCC. Compounds such as curcumin, emodin, gallic acid, and ginsenosides exhibit anti-tumor effects by inhibiting β-catenin nuclear translocation, inducing autophagy, suppressing angiogenesis, and modulating the tumor microenvironment. For example, curcumin inhibits HCC cell proliferation and invasion by downregulating lncRNA expression and EMT markers, thereby inactivating the Wnt/β-catenin signaling pathway. Additionally, alkaloids like tetrandrine and toosendanin reduce metastasis through pathway-specific inhibition and epigenetic modulation. These compounds demonstrate potential as standalone therapies, and also in combination with conventional treatments like sorafenib by enhancing the effectiveness and overcoming resistance. However, challenges such as limited bioavailability, stability, and the intricate interplay of the Wnt/β-catenin pathway with other signaling pathways highlights the need for advanced delivery systems and combination strategies. In conclusion, future research should prioritize clinical validation, precision medicine approaches, and exploration of the role of NBCs in cancer stem cell regulation. Collectively, NBCs targeting the Wnt/β-catenin pathway offer a novel, safer, and multi-faceted approach for improving HCC treatment outcomes, paving the way for their integration into standard therapeutic regimens.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1613-1622"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automatic Real-Time Detection and Diagnosis of Liver Tumor with Ultrasound.","authors":"Chih-Horng Wu, Jin-Chuan Sheu, Pei-Lien Chou, Jonathan Lee, Hsiao-Ching Nien","doi":"10.2147/JHC.S524311","DOIUrl":"10.2147/JHC.S524311","url":null,"abstract":"<p><strong>Background/aim: </strong>Ultrasonography is the most commonly used screening tool for hepatocellular carcinoma (HCC). However, the diagnostic performance of ultrasound is highly operator dependent. We aimed to develop deep learning (DL) models to automatically diagnose and detect hepatic lesions in a larger dataset, with HCC as the dominant malignancy.</p><p><strong>Methods: </strong>We enrolled patients diagnosed with hepatic tumors using abdominal ultrasound between January 2002 and December 2020 in a retrospective cohort with a diagnosis of malignant and benign lesions. A total of 1576 patients with 4599 images and 6001 lesions were analyzed. Deep learning models included ResNet50, Xception, Inception Resnet V2, EfficientNet-B5, EfficientNetV2-S, EfficientNetV2-L, Swin-T, and Swin-B for diagnosis and YOLOR for lesion detection. We analyzed the area under the curve (AUC) to determine the diagnostic performance and choose the best model. The mean Average Precision (mAP) score was then evaluated for real-time lesion detection using the area under the precision-recall curve after the average of each category.</p><p><strong>Results: </strong>The dataset was separated into 1061 in training, 373 in validation, and 142 testing sets. The AUC for ResNet50, Xception, Inception Resnet V2, EfficientNet-B5, EfficientNetV2-S, EfficientNetV2-L, Swin-T, and Swin-B are 0.88, 0.89, 0.88, 0.90, 0.85, 0.89, 0.89, and 0.90, respectively. The mAP scores for detecting and differentiating malignant and benign lesions for YOLOR-W6 and YOLOR-D6 in the validation and testing sets were 0.5134/0.5342 and 0.5410/0.5631.</p><p><strong>Conclusion: </strong>Our study demonstrated that DL models can differentiate between benign and malignant lesions with high accuracy on ultrasound images. Simultaneous DL-based lesion detection and classification are also possible using real-time ultrasonography.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1599-1611"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12301240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Long-Term Outcomes Between Repeated Hepatic Resection and Radiofrequency Ablation in Patients with Small Recurrent Hepatocellular Carcinoma After Initial Curative Resection: A Propensity Score Matched Study.","authors":"Chih-Yang Hsiao, Rey-Heng Hu, Po-Chin Liang, Chih-Horng Wu","doi":"10.2147/JHC.S496470","DOIUrl":"10.2147/JHC.S496470","url":null,"abstract":"<p><strong>Background: </strong>Repeat hepatic resection (re-resection) and radiofrequency ablation (RFA) are both standard treatments for small recurrent hepatocellular carcinoma (HCC) after curative resection. This study compares long-term outcomes of these treatments.</p><p><strong>Methods: </strong>This retrospective study included patients with recurrent HCC smaller than 3 cm treated with re-resection or RFA from 2001 to 2019 in a tertiary center. Propensity score matching (PSM) minimized baseline differences. Primary outcomes were overall survival (OS) and disease-free survival (DFS). Subgroup analyses explored outcomes based on recurrence interval, hepatitis infection status, and RFA guidance method (ultrasound [US] versus computed tomography [CT]). Multivariate Cox regression identified predictors of survival and secondary recurrence.</p><p><strong>Results: </strong>After PSM, 106 patients in the re-resection group and 106 in the RFA group were compared. OS rates at 3, 5, and 8 years for re-resection were 97.9%, 85.4%, and 75.8%, compared to 87.8%, 77.9%, and 62.8% for RFA (p = 0.15). DFS rates were 53.3%, 41.8%, and 26.7% for re-resection versus 43.9%, 28.1%, and 24.0% for RFA (p = 0.15). Subgroup analysis indicated re-resection was superior in early recurrence (<24 months) and HBV-related HCC. US-guided and CT-guided RFA showed no significant differences in OS or DFS. HCV infection and multiple tumors were independent predictors of secondary recurrence.</p><p><strong>Conclusion: </strong>Repeat hepatic resection and RFA offer comparable survival for small recurrent HCC. Re-resection is preferred for early recurrence and HBV-related HCC. US- and CT-guided RFA are equally effective alternatives.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"1587-1598"},"PeriodicalIF":3.4,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12296703/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}